OncLive SOSS

Authors

Kwok-Kin Wong, MD, PhD

Latest:

Dr. Wong on the Current Landscape of NSCLC

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Kyle A. Richards, MD

Latest:

Dr. Richards on Unanswered Questions in Treating Bladder Cancer

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Laila Saied Agrawal, MD

Latest:

Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast Cancer

Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.

Lajos Pustzai, MD, DPhil

Latest:

Dr. Pusztai on the Promise of ctDNA Assays in Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Lajos Pusztai, MD

Latest:

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Lajos Pusztai, MD, DPhil

Latest:

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Lakshmi N. Rajdev, MD

Latest:

Dr. Rajdev on the Efficacy of Pembrolizumab/Chemotherapy in Esophageal Cancer

Lakshmi Rajdev, discusses the efficacy of pembrolizumab (Keytruda) plus chemotherapy in patients with esophageal cancer.

Lalan Wilfong, MD

Latest:

Digital Health and Process Improvements Enhance Community-Based Patient Care

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

Lan G. Coffman, MD, PhD

Latest:

Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression

Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer and high folate receptor-alpha expression.

Lana Hamieh, MD

Latest:

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Lana Kandalaft, PharmD, PhD

Latest:

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Latest:

Reduce Costs By Using Less Radiotherapy

Radiation therapy remains fertile for continued technological innovation that can improve patient outcomes, but of the newest technologies may be practical for only the largest institutions.

Lani Alison, BCN, MS, HCQ, PCMH, CCE

Latest:

Methods on Improving Survivorship and Palliative Care

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Lara Kujtan, MD

Latest:

Dr. Kujtan on Frontline Therapy for EGFR-Positive NSCLC

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses frontline therapy for patients with EGFR-positive non–small cell lung cancer (NSCLC).

Larry Anderson, MD, PhD

Latest:

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Larry J. Copeland, MD

Latest:

Dr. Copeland on the Importance of Germline Testing in Ovarian Cancer

Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.

Larry Kestin MD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Lars Bastholt, MD

Latest:

Dr. Bastholt on Lenvatinib in Thyroid Cancer

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Latest:

A Life Redirected: Pursuing a Nursing Career After Osteosarcoma

In the summer of 2010, 20-year-old physical therapy student Hannah Komai was diagnosed with low-grade osteosarcoma after an incisional biopsy.

Laura C. Michaelis, MD

Latest:

Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.